The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
For discovery or for standardization, Ayurveda colleges/institutes need to collaborate closely with Phytochemists, Pharmacologists, and Toxicologists from premier institutions
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
The use of procalcitonin testing for sepsis management is highest in the US
There is also a growing interest in whole generation sequencing (WGS)
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
The Phase 3 SOLO-1 trial demonstrated 67% of advanced ovarian cancer patients with BRCA mutations receiving LYNPARZA were alive at seven years versus 47% of placebo patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
